27 min
p53abn and no myoinvasion endometrial cancer with Jessica Mcalpine and Amy Jamieson IJGC Podcast
-
- Medicine
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Jessica Mcalpine and Amy Jamieson to discuss p53abn and no myoinvasion endometrial cancer. Dr. Jessica McAlpine is a surgeon-scientist at the University of British Columbia and BC Cancer and a Tier 1 Canada Research Chair. Dr. Amy Jamieson is a gynecologic oncologist at Vancouver General Hospital and BC Cancer and an Assistant Professor at the University of British Columbia.
Highlights:
• p53abn endometrial cancers are aggressive tumours, responsible for the majority of recurrences and death from this disease. The optimal management of patients with stage IA p53abn endometrial cancer without myometrial invasion is debated.
• We demonstrate the recurrence rates in p53abn endometrial cancer stage IA without myometrial invasion were high at 16% and higher still with residual endometrial tumor (19%).
• Recurrence rates in p53abn stage IA without myometrial invasion did not differ compared to p53abn stage IA with myometrial invasion, where adjuvant treatment is routinely recommended.
• Most recurrences in patients with p53abn endometrial cancer stage IA without myometrial invasion were distant (89%) and fatal.
• High rates of distant and unsalvageable recurrences in stage IA p53abn endometrial cancer without myometrial invasion justify a discussion about adjuvant therapy.
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Jessica Mcalpine and Amy Jamieson to discuss p53abn and no myoinvasion endometrial cancer. Dr. Jessica McAlpine is a surgeon-scientist at the University of British Columbia and BC Cancer and a Tier 1 Canada Research Chair. Dr. Amy Jamieson is a gynecologic oncologist at Vancouver General Hospital and BC Cancer and an Assistant Professor at the University of British Columbia.
Highlights:
• p53abn endometrial cancers are aggressive tumours, responsible for the majority of recurrences and death from this disease. The optimal management of patients with stage IA p53abn endometrial cancer without myometrial invasion is debated.
• We demonstrate the recurrence rates in p53abn endometrial cancer stage IA without myometrial invasion were high at 16% and higher still with residual endometrial tumor (19%).
• Recurrence rates in p53abn stage IA without myometrial invasion did not differ compared to p53abn stage IA with myometrial invasion, where adjuvant treatment is routinely recommended.
• Most recurrences in patients with p53abn endometrial cancer stage IA without myometrial invasion were distant (89%) and fatal.
• High rates of distant and unsalvageable recurrences in stage IA p53abn endometrial cancer without myometrial invasion justify a discussion about adjuvant therapy.
27 min